IMMUNOTHERAPY FOR SUPERFICIAL BLADDER CANCER
- 1 August 1992
- journal article
- Published by Elsevier in Urologic Clinics of North America
- Vol. 19 (3) , 549-556
- https://doi.org/10.1016/s0094-0143(21)00421-3
Abstract
No abstract availableThis publication has 35 references indexed in Scilit:
- Humoral and cell-mediated immune responses to live recombinant BCG–HIV vaccinesNature, 1991
- Internalization of Bacille Calmette-Guerin by Bladder Tumor CellsJournal of Urology, 1991
- Topical BCG for recurrent superficial bladder cancerThe Lancet, 1991
- Adjuvant Topical Chemotherapy versus Immunotherapy in Primary Superficial Transitional Cell Carcinoma of the BladderBritish Journal of Urology, 1991
- A Randomized Controlled Study of Intravesical α−2b-Interferon in Carcinoma in Situ of the BladderJournal of Urology, 1990
- Elevations of Cytokines Interleukin-1, Interleukin-2 and Tumor Necrosis Factor in the Urine of Patients after Intravesical Bacillus Calmette-Guerin ImmunotherapyJournal of Urology, 1990
- Expression of Blood Group Precursor T Antigen as a Prognostic Marker for Human Bladder Cancer Treated by Bacillus Calmette-Guerin And Interleukin-2Journal of Urology, 1989
- Detection of Interleukin 2 in the Urine of Patients with Superficial Bladder Tumors after Treatment with Intravesical BCGJournal of Urology, 1986
- The Use of Bacillus Calmette-Guerin in the Therapy of Bladder Carcinoma in SituJournal of Urology, 1985
- Experience with Bacillus Calmette-Guerin in Patients with Superficial Bladder CarcinomaJournal of Urology, 1982